Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has taken significant strides in international ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Hims & Hers Health also provided a longer-term outlook, laying out expectations for at least $6.5 billion in annual revenue for full-year 2030, and adjusted EBITDA of at least $1.3 billion.

Hims & Hers’ stock price has swung wildly this year. The telehealth company’s public feud with drugmaker Novo Nordisk knocked off a nearly a third of its valuation on Monday.

Telemedicine company Hims & Hers Health has been one of the hottest healthcare stocks in recent memory. Changes at UnitedHealth Group have attracted the attention of investors, but a smaller ...

Shares of Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) are surging on Tuesday. The companie' stocks had jumped 24% and 34%, respectively, as of 3:15 p.m. ET as the S&P 500 and the ...

Hims & Hers stock plunged more than 50% at one point. Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more on HIMS stock and both its potential and the risks involved.

Virtual health and wellness platform Hims & Hers Health, Inc. is now offering an injectable weight loss drug with the same active ingredient (semaglutide) as Novo Nordisk’s popular brand-name ...